Abbott Laboratories financials
$100.95−0.03%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.59B | $11.16B | $11.46B | $11.37B | $11.14B | $10.36B | $10.97B | $10.63B | $10.38B | $9.96B | $10.24B | $10.14B |
| Gross profit | $7.27B | $6.27B | $6.54B | $6.29B | $6.29B | $5.89B | $6.03B | $5.94B | $5.77B | $5.50B | $5.68B | $5.54B |
| Gross margin | 57.7% | 56.2% | 57.0% | 55.4% | 56.4% | 56.9% | 55.0% | 55.8% | 55.6% | 55.2% | 55.5% | 54.6% |
| Operating income | $1.69B | $1.34B | $2.25B | $2.06B | $2.05B | $1.69B | $1.91B | $1.86B | $1.67B | $1.39B | $1.78B | $1.65B |
| Net income | $928.0M | $1.08B | $1.78B | $1.64B | $1.78B | $1.32B | $9.23B | $1.65B | $1.30B | $1.23B | $1.59B | $1.44B |
| Net margin | 7.4% | 9.6% | 15.5% | 14.5% | 16.0% | 12.8% | 84.1% | 15.5% | 12.5% | 12.3% | 15.6% | 14.2% |
| Diluted EPS | $0.53 | $0.61 | $1.03 | $0.94 | $1.01 | $0.76 | $5.39 | $0.94 | $0.74 | $0.70 | $0.91 | $0.82 |
| EBITDA | $2.75B | $2.15B | $3.04B | $2.85B | $2.83B | $2.45B | $2.72B | $2.66B | $2.47B | $2.66B | $1.78B | $2.47B |
| Operating cash flow | $2.49B | $1.31B | $3.31B | $2.79B | $2.05B | $1.42B | $2.87B | $2.71B | $1.96B | $1.02B | $3.04B | $1.88B |
| Free cash flow | $1.99B | $916.0M | $2.63B | $2.29B | $1.54B | $933.0M | $2.15B | $2.15B | $1.43B | $627.0M | $2.28B | $1.32B |
| Diluted shares | 1,743.0M | 1,747.1M | 1,716.6M | 1,749.4M | 1,750.8M | 1,747.2M | 1,711.6M | 1,747.6M | 1,751.2M | 1,749.7M | 1,709.7M | 1,748.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.10B | $6.80B | $8.52B | $7.51B | $6.95B | $6.53B |
| Short-term investments | $499.0M | $492.0M | $417.0M | $222.0M | $331.0M | $312.0M |
| Total debt | $32.61B | $34.05B | $12.93B | $12.94B | $13.44B | $13.24B |
| Total assets | $109.22B | $110.43B | $86.71B | $84.18B | $84.00B | $81.45B |
| Total liabilities | $57.45B | $57.73B | $33.94B | $32.92B | $33.17B | $32.38B |
| Shareholders' equity | $51.76B | $52.70B | $52.77B | $51.26B | $50.83B | $49.06B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology